{"id":2981,"date":"2020-09-23T20:37:00","date_gmt":"2020-09-23T20:37:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-group-strategy-has-identified-four-development-directions\/"},"modified":"2022-07-04T20:41:43","modified_gmt":"2022-07-04T20:41:43","slug":"grindeks-group-strategy-has-identified-four-development-directions","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-group-strategy-has-identified-four-development-directions\/","title":{"rendered":"Grindeks koncerna strat\u0113\u0123ija paredz \u010detrus att\u012bst\u012bbas virzienus"},"content":{"rendered":"\n

Akciju sabiedr\u012bba Grindeks inform\u0113, ka ir izstr\u0101d\u0101jusi Grindeks koncerna att\u012bst\u012bbas strat\u0113\u0123iju l\u012bdz 2025. gadam, izvirzot noz\u012bm\u012bg\u0101kos att\u012bst\u012bbas virzienus.<\/p>\n\n\n\n

Grindeks koncerna noz\u012bm\u012bg\u0101kie att\u012bst\u012bbas virzieni ir:<\/p>\n\n\n\n

1) jaunu akt\u012bvo farmaceitisko vielu un gatavo z\u0101\u013cu formu kl\u0101sta papla\u0161in\u0101\u0161ana;
2) darb\u012bbas papla\u0161in\u0101\u0161ana jaunos tirgos \u2013 Eiropas Savien\u012bbas valst\u012bs, ASV, Jap\u0101n\u0101, Dienvidkorej\u0101, Austr\u0101lij\u0101 un Jaunz\u0113land\u0113;
3) ra\u017eo\u0161anas infrastrukt\u016bras papla\u0161in\u0101\u0161ana Latvij\u0101;
4) meitas uz\u0146\u0113muma AS Kalceks att\u012bst\u012bba.<\/p>\n\n\n\n

AS Grindeks strat\u0113\u0123ija paredz, ka uz\u0146\u0113mums turpm\u0101k fokus\u0113sies uz sirds un asinsvadu, centr\u0101lo nervu sist\u0113mu ietekm\u0113jo\u0161o, pretv\u0113\u017ea un diab\u0113ta \u0101rst\u0113\u0161anas medikamentu kl\u0101sta papla\u0161in\u0101\u0161anu. Pl\u0101nots, ka 2025. gad\u0101 produktu kl\u0101stu \u0161aj\u0101s terapeitiskaj\u0101s grup\u0101s veidos 105 gatavo z\u0101\u013cu formas, un t\u0101s tiks eksport\u0113tas uz 97 pasaules valst\u012bm. Lai stiprin\u0101tu savu konkur\u0113tsp\u0113ju un neatkar\u012bbu no \u0101rvalstu akt\u012bvo farmaceitisko vielu ra\u017eot\u0101jiem, tiek pl\u0101nots papla\u0161in\u0101t Grindeks akt\u012bvo farmaceitisko vielu kl\u0101stu l\u012bdz vismaz 40 viel\u0101m 2025. gad\u0101.<\/p>\n\n\n\n

Svar\u012bgs Grindeks koncerna izaugsmes priek\u0161nosac\u012bjums b\u016bs akt\u012bvo farmaceitisko vielu un gatavo z\u0101\u013cu formu ra\u017eo\u0161anas jaudas palielin\u0101\u0161ana, t\u0101p\u0113c att\u012bst\u012bbas pl\u0101ns paredz jaunas ra\u017eotnes b\u016bvniec\u012bbu Latvij\u0101. \u0160obr\u012bd uzs\u0101kta projekta izstr\u0101de un nepiecie\u0161am\u0101 invest\u012bciju apjoma apzin\u0101\u0161ana. Iecer\u0113ts, ka projekts tiks \u012bstenots vair\u0101kos posmos.<\/p>\n\n\n\n

AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: \u201cEsam sasniegu\u0161i t\u0101du Grindeks koncerna att\u012bst\u012bbas stadiju, kas prasa pie\u0146emt \u013coti noz\u012bm\u012bgus, strat\u0113\u0123iski p\u0101rdom\u0101tus l\u0113mumus par ieguld\u012bjumiem uz\u0146\u0113muma n\u0101kotn\u0113. Lai palielin\u0101tu koncerna konkur\u0113tsp\u0113ju Eiropas un pasaules tirgos, k\u0101 ar\u012b sasniegtu ambiciozus m\u0113r\u0137us, mums nepiecie\u0161amas liel\u0101kas gatavo z\u0101\u013cu formu un akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas jaudas. Man k\u0101 akcion\u0101ram un Latvijas patriotam ir svar\u012bgi, ka Latvij\u0101 att\u012bst\u0101s r\u016bpniecisk\u0101 ra\u017eo\u0161ana un eksports. M\u016bsu projekts paredz izveidot jaunu pasaules l\u012bme\u0146a farmaceitisko ra\u017eotni, kas nes\u012bs lielu atdevi ar\u012b Latvijas ekonomikai un veicin\u0101s valsts eksporta pieaugumu.\u201d<\/em><\/p>\n\n\n\n

Grindeks koncerna ilgtermi\u0146a strat\u0113\u0123ija paredz ar\u012b m\u0113r\u0137tiec\u012bgu meitasuz\u0146\u0113muma AS Kalceks att\u012bst\u012bbu, specializ\u0113joties uz medikamentiem slimn\u012bcu segmentam. Pl\u0101nots, ka jau 2020. gad\u0101 Kalceks medikamentu p\u0101rdo\u0161anas r\u0101d\u012bt\u0101js sasniegs 40 milj. eiro.<\/p>\n","protected":false},"excerpt":{"rendered":"

Akciju sabiedr\u012bba Grindeks inform\u0113, ka ir izstr\u0101d\u0101jusi Grindeks koncerna att\u012bst\u012bbas strat\u0113\u0123iju l\u012bdz 2025. gadam, izvirzot noz\u012bm\u012bg\u0101kos att\u012bst\u012bbas virzienus. Grindeks koncerna noz\u012bm\u012bg\u0101kie att\u012bst\u012bbas virzieni ir: 1)…<\/p>\n","protected":false},"author":3,"featured_media":2978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2981"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2981\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2978"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}